Similar language back in March per 3 Putt:
3Putt_4nodough
•
9m ago
In fairness they did state nearly the same verbiage back in March at the announcement of the previous raise.
Net proceeds from the financing will primarily support the advancement of CytoDyn’s clinical development programs, including ongoing and planned trials, regulatory engagement, and data analysis. Additional funds may be allocated toward manufacturing readiness, regulatory and compliance infrastructure, and general working capital.
Now what is of interest to me is how much of the previous BLA submission plus any work Cyrus might have been engaged in (rumor was there was an effort to push forward with HIV submission until well, all heck broke loose) can be used in the next submission. Parts of the BLA:
• Product and Manufacturing Information: This section requires extensive detail on the product's Chemistry, Manufacturing, and Controls (CMC). It must describe the manufacturing facility, the production process, quality control measures, the analytical methods used to characterize the product, and ensure its identity, quality, and consistency between batches.
• Nonclinical Data: The application must include full reports from all nonclinical laboratory and animal studies. This data provides essential information on the product's pharmacology and toxicology, forming the basis for the initial safety assessment before and during human trials.
• Clinical Pharmacological Studies: This section evaluates pharmacological effects of the product on the human body physiology and biochemistry.
• Clinical Data: The BLA must contain the results from all human clinical trials conducted to evaluate the product. This evidence is critical for establishing the product's safety profile in the intended patient population and providing substantial evidence of its effectiveness for the proposed indication.
• Proposed Labeling: The sponsor must submit all proposed labeling, including the Prescribing Information (package insert), patient information leaflets, and container/carton labels. The labeling must accurately and concisely summarize the essential scientific and clinical information needed for the safe and effective use of the product, based on the data provided in the BLA.
A lot of that should be packaged up and ready to go; obviously 3&4 are the long poles of the tent but at least they should not be starting from scratch.
3Putt_4nodough
•
9m ago
In fairness they did state nearly the same verbiage back in March at the announcement of the previous raise.
Net proceeds from the financing will primarily support the advancement of CytoDyn’s clinical development programs, including ongoing and planned trials, regulatory engagement, and data analysis. Additional funds may be allocated toward manufacturing readiness, regulatory and compliance infrastructure, and general working capital.
Now what is of interest to me is how much of the previous BLA submission plus any work Cyrus might have been engaged in (rumor was there was an effort to push forward with HIV submission until well, all heck broke loose) can be used in the next submission. Parts of the BLA:
• Product and Manufacturing Information: This section requires extensive detail on the product's Chemistry, Manufacturing, and Controls (CMC). It must describe the manufacturing facility, the production process, quality control measures, the analytical methods used to characterize the product, and ensure its identity, quality, and consistency between batches.
• Nonclinical Data: The application must include full reports from all nonclinical laboratory and animal studies. This data provides essential information on the product's pharmacology and toxicology, forming the basis for the initial safety assessment before and during human trials.
• Clinical Pharmacological Studies: This section evaluates pharmacological effects of the product on the human body physiology and biochemistry.
• Clinical Data: The BLA must contain the results from all human clinical trials conducted to evaluate the product. This evidence is critical for establishing the product's safety profile in the intended patient population and providing substantial evidence of its effectiveness for the proposed indication.
• Proposed Labeling: The sponsor must submit all proposed labeling, including the Prescribing Information (package insert), patient information leaflets, and container/carton labels. The labeling must accurately and concisely summarize the essential scientific and clinical information needed for the safe and effective use of the product, based on the data provided in the BLA.
A lot of that should be packaged up and ready to go; obviously 3&4 are the long poles of the tent but at least they should not be starting from scratch.
1
